Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2025-12-24 @ 9:28 PM
NCT ID:
NCT00761332
Eligibility Criteria:
Inclusion Criteria:
* Men and postmenopausal women who have a previous vertebral osteoporotic fracture that was sustained at least 6 weeks prior to joining the study.
* Patients who are free of severe or chronically disabling conditions other than osteoporosis.
* Patients who are not currently receiving and have not previously received teriparatide.
* Patients who agree to participate, return to follow-up visits, and who have signed informed consent to participate in the study.
* Patients, who in the opinion of the prescribing physician, are eligible to receive the intended treatment and comply with all the recommendations stated in the relevant product information.
Exclusion Criteria:
* Are investigator site personnel directly affiliated with the study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
* Are Lilly employees (that is, employees, temporary contract workers, or designees responsible for conducting the study). Immediate family of Lilly employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility.
* Patients who have any contraindications according to the relevant product information in the country in which they are being treated.
* Patients who are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT00761332
Study Brief:
Protocol Section:
NCT00761332